RT Journal Article
SR Electronic
T1 Correction: PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e006833corr1
DO 10.1136/jitc-2023-006833corr1
VO 12
IS 1
YR 2024
UL http://jitc.bmj.com/content/12/1/e006833corr1.abstract